Erasmus MC
Rotterdam, Netherlands
Location status: Recruiting
NCT Number: NCT06859957
Low back pain is one of the conditions causing more disability worldwide. The use of pain medications is substantial in patients with chronic LBP. But the efficacy of commonly used analgesics is modest. More than half of patients with chronic LBP also has sleep problems. In recent years, some preliminary studies have shown a promising effect of melatonin for the treatment of pain.
The objective of this study is to investigate the efficacy of melatonin, relative to placebo, in patients with chronic LBP.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Phase 3
Rotterdam, Netherlands
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 mg melatonin daily for a period of 6 weeks
Daily placebo for a period of 6 weeks
Time frame: from baseline to end of treatment at 6 weeks
Change in low back pain intensity (average pain intensity past 7 days), measured on a 0-10 Numeric Rating Scale (NRS) where 0 means no pain and 10 means worst pain imaginable, from baseline to 6 weeks
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Back pain-related disability is measured using the Roland Morris Disability Questionnaire (RMDQ). The RMDQ outcome ranges from 0-24, where a higher score means more disability.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Using Global perceived effect (GPE) questionnaire (7-point scale), where a score of 1 means highly satisfied/ great recovery and a score of 7 means highly dissatisfied / poor recovery.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Physical and mental health measured using the PROMIS Global Health questionnaire.
A 10 items questionnaire, items are scored from 1-5 where a score of 5 is the best outcome and a score of 1 is the worst outcome.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Measured using the EQ-5D-5L (questionnaire).
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS (0-100) records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Measured using the Insomnia Severity Index (ISI) (questionnaire). The questionnaire consists of 7 questions, all scored with a score ranging from 0-3. The total score ranges from 0 (no sleeping problems) to 28 (severe sleeping problems)
Time frame: baseline to 3 months and 6 months follow-up
Using a questionnaire
Time frame: baseline to end of treatment at 6 weeks
Measured using the Beck Depression Inventory (BDI) (questionnaire). A 21-item questionnaire, every item is scored from 0-3. This leads to a total score from 0 (best outcome) to 63 (worst outcome)
Time frame: baseline to end of treatment at 6 weeks
Measured using the Pain Anxiety Symptoms Scale (PASS) (questionnaire). A 40-item questionnaire (ranging from 0-200), where a high score means high pain related anxiety.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Measured using PainDETECT (questionnaire). A 9-item questionnaire, with 7 weighted descriptor items (from never to very strongly) and 2 items related to spatial and temporal pain characteristics.
A total score of 19 or more is indicative of likely neuropathic pain.
Time frame: baseline to 3 months and 6 months follow-up
iMTA Productivity Cost Questionnaire is used. The questionnaire consists of 18 questions in total. To calculate the costs of production losses, volumes are multiplied by unit costs.
Time frame: baseline to 3 months and 6 months follow-up
Direct costs of medical care measured using iMCQ Medical Consumption Questionnaire.
The questionnaire consists of 29 items. Questions are answered with yes/no, or participants are asked to fill in a number, for example "How many appointments with the physiotherapist did you have in the past 3 months?". The costs of medical consumption are calculated by multiplying measured volumes of care by the cost price per unit of care.
Time frame: baseline to end of treatment at 6 weeks and 3 months and 6 months follow-up
Using questionnaire according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: 7 days during treatment period
A GENEActiv activity tracker is worn for a period of 7 days during the 6-week treatment period by a subgroup of 60 participants. This device can measure activity and sleep. This measure is use as an explorative objective and only descriptive statistics of the data will be given. GENEActiv software is used to analyse the data.
Time frame: 7 days during treatment period
A GENEActiv activity tracker is worn for a period of 7 days during the 6-week treatment period by a subgroup of 60 participants. This device can measure activity and sleep. A sleep report is created using the GENEActiv software. This measure is used as an explorative measure, only descriptive statistics are done.
Contact information is provided by the study sponsor or research team.
Bart Koes
Other
Melatonin for Patients With Chronic Low Back Pain - a Randomized Placebo-controlled Trial
Acronym: MELBACK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07494162
Chronic Low-back Pain (cLBP), Muscular Diseases
Sacramento, California, United States
View Trial DetailsNCT04982965
Back Pain, Bone Diseases
La Jolla, California, United States
View Trial DetailsNCT07351851
Chronic Low-back Pain (cLBP), Female Urogenital Diseases
Doha, Baladiyat ad Dawhah, Qatar
View Trial DetailsNCT06999772
Chronic Low-back Pain (cLBP), Chronic Pain
Québec, Quebec, Canada
View Trial Details